** Shares of medical device maker Tivic Health Systems TIVC.O rise 232.6% to $11.82 premarket
** TIVC says it provided briefings at the White House and FDA which secured positive interest in potential military and defense applications for its biologic and bioelectronic product candidates
** Both meetings were held last week in Washington D.C. - TIVC
** Separately, co says it discussed the potential for expedited pathways and support for export opportunities for its lead experimental immunotherapy drug called entolimod
** Entolimod is being tested in a late-stage study in patients to treat acute radiation syndrome $(ARS.UK)$, a condition caused by exposure to high doses of ionizing radiation
** As of last close, TIVC had fallen 40.5% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。